Back to News
Market Impact: 0.35
Keros Therapeutics, Inc. Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Keros reported third-quarter 2026 net income of $14.2 million, versus a net loss of $7.3 million in the third quarter of 2025. The article attributes the approximately $21.4 million improvement primarily to revenue recognized in 2026 under Keros’ license agreement with Tak…; the provided text ends before identifying the counterparty or giving further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
TAK0.30
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens